ID: ALA3941484

Max Phase: Preclinical

Molecular Formula: C27H30N4O4

Molecular Weight: 474.56

Molecule Type: Small molecule

Representations

Canonical SMILES:  O=C(NC[C@@H](C(=O)NO)N1CCCCC1)c1ccc(OCc2ccnc(-c3ccccc3)c2)cc1

Standard InChI:  InChI=1S/C27H30N4O4/c32-26(29-18-25(27(33)30-34)31-15-5-2-6-16-31)22-9-11-23(12-10-22)35-19-20-13-14-28-24(17-20)21-7-3-1-4-8-21/h1,3-4,7-14,17,25,34H,2,5-6,15-16,18-19H2,(H,29,32)(H,30,33)/t25-/m0/s1

Standard InChI Key:  HMKOPGQRIXEHTH-VWLOTQADSA-N

Molecule Features

Natural Product: No

Oral: No

Chemical Probe: No

Parenteral: No

Molecule Type: Small molecule

Topical: No

First In Class: No

Black Box: No

Chirality: No

Availability: No

Prodrug: No

Properties

Molecular Weight: 474.56

Molecular Weight (Monoisotopic): 474.2267

AlogP: 3.42

#Rotatable Bonds: 9

Polar Surface Area: 103.79

Molecular Species: NEUTRAL

HBA: 6

HBD: 3

#RO5 Violations: 0

HBA (Lipinski): 8

HBD (Lipinski): 3

#RO5 Violations (Lipinski): 0

CX Acidic pKa: 8.72

CX Basic pKa: 6.30

CX LogP: 3.18

CX LogD: 3.12

Aromatic Rings: 3

Heavy Atoms: 35

QED Weighted: 0.32

Np Likeness Score: -0.93

References

1.  (2016)  4-alkoxy-N-(2-hydroxycarbamoyl-2-piperidinyl-ethyl)-benzamide compounds as selective TACE-inhibitors for the treatment of inflammatory diseases, 

Source

Source(1):

• BindingDB Database